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Summary  
 
Fungi such as Aspergillus and Canadida are ubiquitous in nature and can lead to severe lung infections. 
When treating these conditions, one must consider targeted drug delivery to the lung. Amphotericin B is the 
drug of choice for the treatment of fungal lung infections. Pulmonary delivery of antifungal agents is 
complicated as a result of their poor aqueous solubility and toxicity. Amphiphilic chitosan derivatives may be 
particularly appropriate for this application. The amphiphilic nature is achieved by the addition of the 
hydrophobic group: Palmitoyl and hydrophilic group: PEG, which will also enhance the stability and 
hydrophobic nature of polymer. These carriers can form micelles or complexes which are in the size range 
40-50 nm + 7.89 nm with a charge of +9-11 mv + 1.55 mV. Grafting was confirmed by FT-IR and 1H NMR. 
Thermodynamic properties were also determined by Differential Scanning Calorimetry, which showed a 
glass transition temperature of 135°C. Transmission Electron Microscopy showed small and uniform 
spherical micelles/complexes were produced. UV spectroscopy was used to assess the drug loading 
efficiency within the carriers, showing a value of 30-40% with 1:10 ratio of the drug:polymer and 50-60 % 
with 1:5 ratio of the drug:polymer. Aerosol deposition properties were assessed using a Twin Stage Impinger 
following delivery from a iet nebuliser, Which gave deposition of 65.28 + 1.1 % in stage 2. No toxic effects of 
amphiphilic chitosan derivative were observed in bronchial epithelial cultured cell lines up to a range of 
500mcg/ml  
 
Introduction  
 
Aspergillus and Candida species are transmitted via inhalation and may cause colonisation of the airways  
(alveolar macrophages) leading to life threatening diseases, especially in immunosuppressed patients (Vyas 
et al., 2005; Gilani et al., 2011) . It is very difficult to treat lung fungal infections as, systemic delivery does 
not efficiently deliver drugs to the site of infection, and most of the antifungal agents are toxic. Amphotericin 
B is the drug of choice for systemic fungal infections but produces nephrotoxicity which is dose limiting and 
can cause permanent harm (Albasarah et al., 2010). To reduce toxicity associated with amphotericin B, it 
should be targeted to the site of infection so that there will be no interaction of drug with non-targeted 
tissues. However it has very poor solubility in many organic solvents and is completely insoluble in water, 
this combined with toxicity necessitates the use of delivery system for delivery of amphotericin B to the lung 
(Vyas et al., 2005). In the literature Chitosan based liposomes and micelles have been used for the delivery 
of amphotericin B by nebulisation (Albasarah et al.,2010; Gilani et al., 2011).  
 
Chitosan is an aminopolysaccharide obtained by partial alkaline deacetylation of chitin from a number of  
invertebrates (crustaceans’ exoskeleton, insects’ cuticles etc) and cell walls of fungi and others. (Joshi and 
Sinha, 2006; Inmaculada et al.2010). Chitosan is a hydrophilic polymer, offering attractive properties like  
biocompatibility, biodegradability, low-toxicity, non-immunogenicity, non-carcinogenicity, stability, 
abundance, antifungal and antimicrobial properties (Tong et al., 2005; Joshi et al., 2006; Huang et al., 2010). 
Insolubility in organic solvents and water are major disadvantages of chitosan. To overcome this, in this 
study a hydrophobic group such as palmitoyl was added at the O-position and then PEG was conjugated. 
PEG imparts increased stability and additional hydrophilic nature to chitosan. Hydrophobic group can be 
attached at two positions, either at O-Acyl or at N-Acyl position, but the addition of a hydrophobic group 
does not improve solubility in chlorinated solvent, such as chloroform and dichloromethane. This solubility is 
improved with grafting of the hydrophobic group at the O-Acyl position. The overall carrier is amphiphilic, 
forming micelles which are small in size. Micelles form a hydrophobic core and hydrophilic shell hence 
providing a good carrier system for the delivery of hydrophobic drugs, with the latter being encapsulated in 
the hydrophobic core. Polymeric micelles are mechanically more stable (Zhang et al., 2007). The 
polycationic nature of chitosan potentially also increases delivery of the drug to the negatively charged lung 
airway.  
 
Pulmonary drug delivery utilises nebulisers, dry powder inhalers (DPI) and pressurized metered dose 
inhalers (pMDI) for the delivery of drug components either in the form of a solution/suspension or dry 
powder. With a nebuliser drug can be inhaled during normal breathing through a mouth piece or face mask, 
increasing its suitability for elderly patients and children. In additions, nebulisers also deliver relatively large 
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volumes of solution/suspensions and are therefore suitable for drugs with larger therapeutic doses 
(McCallion et al., 1996). The aim of this study was to synthesis and characterise O- palmitoyl chitosan-PEG 
carriers for the delivery of amphotericin B to the lung using jet nebuliser.  
 
Materials:  
 
Chitosan [molecular weight (MV) = 3-5K] was purchased from Kitto Life Co. Ltd (South Korea). Amphotericin 
B, methane sulfonic acid, palmitoyl chloride, sodium bicarbonate and dimethyl sulfoxide (DMSO) were 
obtained from Sigma Aldrich Co. Ltd., UK. Methanol, dichloromethane and chloroform purchased from 
Fisher Co. Ltd., UK. mPEG NHS was purchased from Advanced Polymer Materials Inc., Canada.  
 
Methods:  
 
Synthesis of O- palmitoyl chitosan-PEG  
 
O- palmitoyl chitosan was synthesized according to procedure described by Huang et al 2010, with some  
modification. Chitosan was dissolved in methane sulfonic acid and palmitoyl chloride was added to this 
solution. The reaction was stopped by the addition of ice. The solution was dialyzed against water and 
treated with sodium bicarbonate and again dialyzed against water. The solution was then lyophilized to 
produce O- palmitoyl chitosan. Thereafter, the O- palmitoyl chitosan produced was conjugated with PEG by 
dissolving mPEG NHS and O- palmitoyl chitosan in anhydrous dichloromethane. The product of this reaction 
was dialyzed against water. The solution was lyophilized to get novel O- palmitoyl chitosan-PEG.  
 
Producing Nanocarriers:  
 
The thin film method was used to produce nanocarriers with O- palmitoyl chitosan-PEG and amphotericin B,  
where chloroform and methanol were used as solvents and the film was hydrated with water at 60°C.  
 
Characterisation:  
 
The polymers produced were then characterized for solubility, grafting by FT-IR and 
1
H NMR, size and zeta  
potential, morphology was seen with Transmission Electron Microscopy by dispersing 2 mg of polymer in 
water and the thermal properties were determined by Differential Scanning calorimetry (DSC). In vitro testing 
of polymer for MTT assay to determine cell viability on exposure to O- Palmitoyl Chitosan-PEG was 
performed using a bronchial epithelial (16HBE 14o-) cell line, seeding was done in 96 well plates and treated 
with increasing concentration of O- palmitoyl Chitosan (0-100 mcg/ml) for 24 h and absorbance was 
measured using spectroscopy at 570 nm and was corrected for background absorbance.  
 
Nanocarriers were characterized for size and zeta potential, surface morphology by Transmission Electron  
Microscopy, drug loading by UV and aerosol deposition characteristics were determined following delivery 
from a jet nebuliser (Pari LC Sprint) into a Twin Stage Impinger (Copley Instruments, UK) operated at 
60L/min with water as collection medium in the two stages.  
 
 Results and Discussion:  
 
O- palmitoyl chitosan showed good solubility in water and organic solvents like chloroform, DCM and 
DMSO. Polymer was dissolved in water and characterized by a Malvern Zeta sizer Nanozs (Malvern 
Instruments Ltd., UK) for size and zeta potential. Mean size was in the range of 45 + 7.89 nm. Zeta potential 
was positive and in the range of 13.5 + 4.61 mV. Morphology was observed using a Philips CM 120 BioTwin 
transmission electron microscope (Philips Electron Optics BV, The Netherlands) and showed uniform, 
spherical micelles of a smaller size as shown in Fig. 1 (a). FT-IR of chitosan and its derivatives was 
undertaken using a Perkin Elmer FT-IR spectrometer, as shown in Fig 4. FT-IR of chitosan and its 
derivatives showed chitosan peaks at 1150, 1059, 1026 and 893 cm-1, palmitoyl peaks at 2917, 2850 and 
1737 cm-1 and PEG groups are seen at 2852, 951 and 845 cm-1. Additional information of acyl chitosan 
was obtained by 
1
H NMR (CDCl3), shown in Fig. 2, which showed peaks for the palmitoyl group at 0.90 (t, 
3H), 1.10-1.45 (m 27.6H), 1.61 (s, 2.6H), 1.8-2.1 (br, 0.3H), 2.35 (m, 2.6H), 2.7-2.9 (br, 0.5H) and 3.2-5.2 
(m, 4.3H) ppm. DSC showed a Tg value at 135°C indicating the amorphous nature of polymer.  
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Fig. 1: TEM image a) O- palmitoyl Chitosan-PEG micelles b) Amphotericin B loaded micelles 
 
 
 
 
 
 
 
 
 
 
 
     
               
 
 
Fig. 2: 
1
H NMR of O-palmitoyl chitosan-PEG 
 
Exposure of the cell line to increasing concentrations (62.5 – 500 mcg/ml) of O-palmitoyl chitosan -PEG, 
resulted in equivalent cell viability to control (Fig. 3), with 81.82 ± 16.08 % of cell viability at 500 mcg/ml. 
However, increasing the dose to 1000 mcg/ml resulted in cell viability at 53.74 % ± 12.96. Therefore 
formulations are relatively non-toxic up to 500 mcg/ml.  
 
 
 
Fig. 3: Concentration Vs Cell viability of O- palmitoyl chitosan-PEG 
 
Nanocarriers containing amphotericin B were characterized for size and zeta potential using a Malvern Zeta 
sizer Nanozs (Malvern Instruments Ltd., UK), giving a mean size of 45 + 7.89 nm and zeta potential of +10 + 
1.55 mV. Although the size of these carriers was seen to be the same as that of the polymer without drug, 
there was a slight reduction in the zeta potential. Drug loading efficiency was assessed using a Perkin Elmer 
UV lamda 25 spectrometer. According to the ratio of drug:polymer used, the drug loading was seen to range 
from 25-40 % and 40-60 %, with the higher drug loading being achieved in the formulation with a lower ratio 
of drug to polymer.  
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Fig. 4: FT-IR of O, Palmitoyl Chitosan-PEG: a) O, almitoyl Chitosan-PEG, b) Comparison of Chitosan, O  
Palmitoyl Chitosan-PEG, mPEG NHS and O, Palmitoyl Chitosan-PEG.  
 
On aerosolisation of the polymer with drug, using a jet nebuliser, 65% of the drug was deposited in to the 
lower stages of the impinger as fine particle fraction  
 
Conclusions:  
 
Positively charged, small, spherical micelles which were uniform in size distribution were produced with O- 
palmitoyl chitosan-PEG, with up to 50% of drug loading efficiency. Positively charged micelles can efficiently  
deliver the negatively charged antifungal agent amphotericin B to the negatively charged lung, hence 
offering a potential carrier for pulmonary delivery of amphotericin B. In vitro cell culture studies showed non 
toxicity of formulation at concentrations up to 500 mcg/ml.  
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